0001654954-24-007637.txt : 20240612 0001654954-24-007637.hdr.sgml : 20240612 20240612111929 ACCESSION NUMBER: 0001654954-24-007637 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240612 FILED AS OF DATE: 20240612 DATE AS OF CHANGE: 20240612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GSK plc CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15170 FILM NUMBER: 241037781 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS FORMER COMPANY: FORMER CONFORMED NAME: GSK PLC DATE OF NAME CHANGE: 20220516 FORMER COMPANY: FORMER CONFORMED NAME: GLAXOSMITHKLINE PLC DATE OF NAME CHANGE: 20010105 6-K 1 a1818s.htm DIRECTOR/PDMR SHAREHOLDING a1818s
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of June 2024
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
GSK plc (the 'Company')
​
Transaction notification
​
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Emma Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
8 (partnership shares)
 
 
 
£16.2324
8 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
16 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Julie Brown
 
b)
Position/status
Chief Financial Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
8 (partnership shares)
 
 
 
£16.2324
8 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
16 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
James Ford
 
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
8 (partnership shares)
 
 
 
£16.2324
8 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
16 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Sally Jackson
 
b)
Position/status
SVP, Global Communications and CEO Office
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
8 (partnership shares)
 
 
 
£16.2324
8 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
16 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
David Redfern
 
b)
Position/status
President Corporate Development
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
8 (partnership shares)
 
 
 
£16.2324
8 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
16 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Regis Simard
 
b)
Position/status
President, Global Supply Chain
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
7 (partnership shares)
 
 
 
£16.2324
7 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
14 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Philip Thomson
 
b)
Position/status
President, Global Affairs
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
7 (partnership shares)
 
 
 
£16.2324
7 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
14 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Deborah Waterhouse
 
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
7 (partnership shares)
 
 
 
£16.2324
7 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
14 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Victoria Whyte
 
b)
Position/status
Company Secretary
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 
c)
Price(s) and
volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2324
8 (partnership shares)
 
 
 
£16.2324
8 (matching shares)
 
 
 
 
 
 
d)
Aggregated
information
 
 
Aggregated volume
 
Price
16 Ordinary Shares
 
£16.2324
 
e)
Date of the transaction
2024-06-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: June 12, 2024
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc